Dolphin Vision

Company Overview

Snapshot

Founded in April 2018 by Gennady Simanovsky and Michael Farber, Dolphin Vision operates with 1–10 employees. The company has raised $78.5K across two funding rounds from two investors. In March 2018, the company secured its first funding round.

Business overview

Dolphin Vision develops advanced air freshener systems designed to neutralize airborne viral pathogens in commercial and public indoor spaces. Its core product, Arothera, utilizes gentle therapeutic diffusion of all-natural, plant-based aroma blends to actively destroy aerobic pathogens. This technology provides continuous protection against common airborne diseases such as Influenza, COVID-19, Avian Flu, and Tuberculosis. The company serves various markets, including offices, clinics, hotels, and transit hubs, operating within the Health Tech & Life Sciences sector.

Strategic signal

In July 2025, Dolphin Vision initiated beta testing for an AI-powered pool monitoring system at a country club in Jerusalem. This strategic move indicates the company's potential expansion beyond air purification into broader safety and operational efficiency solutions within the Leisure & Hospitality industry, leveraging AI for risk mitigation and customer acquisition.

Company Intelligence Q&A

What is Dolphin Vision's primary offering?

Dolphin Vision provides advanced air freshener systems that neutralize airborne viral pathogens using natural, plant-based aroma blends, designed for commercial and public indoor spaces.

Who founded Dolphin Vision and when?

Dolphin Vision was founded in April 2018 by Gennady Simanovsky and Michael Farber.

What was a recent strategic initiative by Dolphin Vision?

In July 2025, Dolphin Vision began beta testing an AI-powered pool monitoring system at a country club in Jerusalem, focusing on drowning detection, real-time alerts, and operational analytics.

What is the total capital raised by Dolphin Vision?

Dolphin Vision has raised a total of $78.5K across two funding rounds.